9-cis-retinoic acid capsules in the treatment of AIDS-related Kaposi sarcoma: Results of a phase 2 multicenter clinical trial

Archives of Dermatology

Volumn 139, Issue 2, 2003, Pages 178-186

  Aboulafia, David M ^a   Norris, Dorece ^b   Henry, David ^c   Grossman, Ronald J ^d   Thommes, James ^e   Bundow, Denise ^a   Yocum, Richard C ^e   Stevens, Victor ^f  

^a VIRGINIA MASON MEDICAL CENTER   (United States)

^b Center for Quality Care   (United States)

^c GRADUATE HOSPITAL   (United States)

^d Anderson Clinical Research   (United States)

^e Pacific Oaks Medical Group   (United States)

^f LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CD4 ANTIGEN;

ADULT; AIDS RELATED COMPLEX; ALOPECIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CHEILITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG CAPSULE; DRUG EFFECT; DRUG ERUPTION; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERANCE; DRY SKIN; EXFOLIATIVE DERMATITIS; HAIR DISEASE; HEADACHE; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; INSOMNIA; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAIL DISEASE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SKIN BIOPSY; T LYMPHOCYTE; TREATMENT OUTCOME; VASODILATATION; XEROSIS; XEROSTOMIA;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; CAPSULES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM STAGING; RISK ASSESSMENT; SARCOMA, KAPOSI; SINGLE-BLIND METHOD; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; TRETINOIN;

EID: 0037319957     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.139.2.178     Document Type: Article

References (41)

1. Biggar RJ, Rabkin CS. The epidemiology of AIDS-related neoplasms. Hematol Oncol Clin North Am. 1996;10:997-1010.
2. Centers for Disease Control. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:1-19.
3. Von Roenn JH, Krown SE. Management of AIDS-associated Kaposi's sarcoma: a multidisciplinary perspective. Oncology. 1998;12(2, suppl 3):1-24.
4. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol. 1996;14:2353-2364.
5. Gill PS, Mitsuyasu RT, Montgomery T, et al. AIDS Clinical Trials Group Study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma. Cancer J Sci Am. 1997;3: 278-283.
6. Stewart S, Jablonowski H, Goebel FD, et al, for the International Pegylated Liposomal Doxorubicin Study Group. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. J Clin Oncol. 1998;16:683-691.
7. Northfeldt DW, Dezube BJ, Thommes JA, et al. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol. 1998;16:2445-2451.
8. Gill PS, Tupule A, Espina-BM, et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol. 1999;17:1876-1883.
9. Allenby G, Bocquel MT, Saunders M, et al. Retinoic acid receptors and retinoid X receptors: interactions with endogenous retinoic acids. Proc Natl Acad Sci U S A. 1993;90:30-34.
10. Lippman SM, Parkinson DR, Itri LM, et al. 13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst. 1992;84:235-241.
11. Corbeil J, Rapaport E, Richman DD, Looney DJ. Antiproliferative effect of retinold compounds on Kaposi's sarcoma cells. J Clin Invest. 1994;93:1981-1986.
12. Guo WX, Gill PS, Antakly T. Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. Cancer Res. 1995;55:823-829.
13. Motzer RJ, Schwartz LS, Law TM, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol. 1995;13:1950-1957.
14. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med. 1990;323:795-801.
15. Tallman MS, Andersen JW, Schiffer CA, et al. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med. 1997;337:1021-1028.
16. Boehm MF, Heyman RA, Patel S, et al. Retinoids: biological function and use in the treatment of dermatological diseases. Expert Opin Investig Drugs. 1995;4: 593-612.
17. Duvic M, Friedman-Kien AE, Looney DL, et al. Topical treatment of cutaneous lesions of AIDS-related Kaposi's sarcoma using 9-cis-retinoic acid gel: results of phase I-II trials. Arch Dermatol. 2000;136:431-442.
18. Walmsley S, Northfelt DW, Melosky B, et al. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. J Acquir Immune Defic Syndr. 1999;22:235-246.
19. Tompkins C, Kean Y, Yocum R. Efficacy and safety of long-term alitretinoin gel (Panretin) for cutaneous AIDS-related Kaposi's sarcoma [abstract]. J Acquir Immune Defic Syndr. 2000;23:A22.
20. Krown SE, Metroka C, Wernz JC, for the AIDS Clinical Trials Group Oncology Committee. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. J Clin Oncol 1989; 7:1201-1207.
21. Food and Drug Administration. COSTART: Coding Symbols forthe Thesaurus of Adverse Reaction Terms. Rockville, Md: National Press Office; 1995. Publication FDA/CDER-95-24.
22. Krown SE, Testa MA, Huang J, for the AIDS Clinical Trials Group Oncology Committee. AIDS-related Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group Staging Classification. J Clin Oncol. 1997;15:3085-3092.
23. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations of the International AIDS Society-USA Panel. JAMA. 1997;277:1962-1969.
24. Aboulafia DM, Bundow D, Weaver C, Yokum RC. Retinoid-induced hypercalcemia in a patient with Kaposi's sarcoma associated with acquired immunodeficiency syndrome. Am J Clin Oncol. 1998;21:513-517.
25. Ziegler JL, Volberding PA, Itri LR. Failure of isotretinoin in Kaposi's sarcoma [letter]. Lancet. 1984;8403:641.
26. Lewi D, Reboredo G, Jauregui Rueda H, et al. Phase II trial of 13-cis-retinoic acid (CRA) in AIDS-related Kaposi's sarcoma (KS). Proc Annu Meet Am Assoc Cancer Res. 1995;14:A835.
27. Bower M, Fife K, Landau D, Gracie F, Phillips RH, Gazzard BG. Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma. Int J STD AIDS. 1997;8:518-552.
28. Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon-alfa-2a in patients with epidemic Kaposi's sarcoma. J Clin Oncol. 1995;13:1966-1974.
29. Gill PS, Espina BM, Moudgil T, et al. All-trans-retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study. Leukemia. 1994; 8(suppl 3):S26-S32.
30. Saiag P, Pavlovic M, Clerici T, et al, for the Kaposi's Sarcoma ANRS Study Group. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential non-randomized phase II trial. AIDS. 1998;12:2169-2176.
31. Bonhomme L, Fredj G, Maurisson G, Einstein E, Misset JL, Jasmin C. Systemic treatment of AIDS-associated Kaposi's sarcoma (KS) with all-trans-retinoic acid (ATRA) [abstract]. Intl Conference AIDS. 1993;9:395.
32. Miles SA, Dezube BJ, Lee JY, et al. Antitumor activity of oral 9-cis-retinoic acid in HIV-associated Kaposi's sarcoma. AIDS. 2002;16:421-429.
33. Sidell N, Taga T, Hirano T, Kishimoto T, Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol. 1991;146:3809-3814.
34. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1 protease inhibitor-associated peripheral lipodystrophy, hyperlipidemia, and insulin resistance. Lancet. 1998;351:1881-1883.
35. Palella FJ, Delaney KM, Moorman AC, et al, for the HIV Outpatient Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
36. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med. 1999;340:1075-1079.
37. Autran B, Carcelain G, Li TS, et al. Positive effects of combined antiretroviral therapy on CD4+ T-cell homeostasis and function in advanced HIV disease. Science. 1997; 277:112-116.
38. Holkova B, Takeshita K, Cheng DM, et al. Effect of highly active antiretroviral therapy on survival in patients with AIDS-associated pulmonary Kaposi's sarcoma treated with chemotherapy. J Clin Oncol. 2001;19:3848-3851.
39. Aboulafia DM. Regression of acquired immunodeficiency syndrome-related pulmonary Kaposi's sarcoma after highly active antiretroviral therapy. Mayo Clin Proc. 1998;73:439-443.
40. Wiggins CL, Aboulafia DM, Ryland LM, Buskin SE, Hopkins SG, Thomas DB. Decline in HIV-associated Kaposi's sarcoma (KS) and non-Hodgkin's lymphoma (NHL) following the introduction of highly active antiretroviral therapy [abstract]. J Acquir Immune Defic Syndr. 1999;21:415.
41. Volm MID, Wernz J. Patients with advanced AIDS-related Kaposi's sarcoma (EKS) no longer requires [sic] systemic therapy after introduction of effective antiviral therapy [abstract]. Proc Annu Meet Am Soc Clin Oncol. 1997;16: A162.